Summary

The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029. The growth of the oral proteins and peptides market has been significantly driven by its increasing demand of oral peptides for the treatment of chronic diseases such as diabetes and CNS disorders, increasing R&D investment by key players for the development and launch of innovative oral peptides and continuous advancements in drug delivery technologies. However, high development cost and the hurdles in formulation and stability are restraining market growth.
“The semaglutide molecule segment accounted for the largest share by molecule in 2023.”
In 2023, the semaglutide segment accounted for the largest share by molecule in the global oral proteins and peptides market. Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. It is used for the management of type-2 diabetes and obesity. Semaglutide works by enhancing insulin secretion in response to elevated blood glucose, reducing glucagon release (which raises blood sugar), and promoting a feeling of fullness after eating, which can help reduce food intake. Oral semaglutide (Rybelsus) is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist product approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely used and recommended for the management of type 2 diabetes.
“The US has continued to dominate the oral proteins and peptides market during the forecast period of 2024-2029.”
The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of oral proteins and peptides in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), Pfizer Inc. (US)
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of key Companies Profiled in the Report:
Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)
Research Coverage:
This research report categorizes the oral proteins and peptides market by molecule (Trofinetide, Semaglutide, Linaclotide, Voclosporin, Plecanatide, Calcitonin, and Others), by Drug Class (Analog of Glycine-Proline-Glutamate (GPE), Glucagon Like Peptide-1 (GLP-1) Receptor Agonist, Guanylate Cyclase-C Agonists, Calcineurin-Inhibitor Immunosuppressant, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, and Others), by Therapeutic Area (Genetic Disorder, Diabetes, Nephrology, Gastroenterology, CNS Disorders, Obesity & Overweight, and Others) by Formulation (Tablet, Capsules, and Oral Solution), by End User (Home Care Settings, Long-Term Care Facilities, Hospitals & Specialty Clinics) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the oral proteins and peptides market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, Advancements in Drug Delivery Technologies, Patient Preference and Compliance for oral route of drug administration, Increasing adoption of inorganic growth strategies such as collaboration and agreement), restraints (High cost is associated with drug development, Contraindication of oral proteins and peptides, Stringent regulatory approval process), opportunities (Robust clinical trial pipeline for oral proteins and peptides drug, Growing demand for non-invasive and patient-friendly treatment options), and Challenges (Hurdles in formulation and stability, Availability of alternative therapies) influencing the growth of the market).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the oral proteins and peptides market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 INCLUSIONS & EXCLUSIONS 34
1.3.3 YEARS CONSIDERED 34
1.3.4 CURRENCY CONSIDERED 35
1.4 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
2.1.1 SECONDARY DATA 37
2.1.2 PRIMARY DATA 37
2.2 MARKET SIZE ESTIMATION 39
2.2.1 INSIGHTS FROM PRIMARIES 41
2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL 41
2.3 MARKET GROWTH FORECAST 42
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 44
2.5 STUDY ASSUMPTIONS 45
2.6 RESEARCH LIMITATIONS 45
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW 51
4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2023) 52
4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2023 52
4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2024 VS. 2029 53
4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Increasing burden of chronic diseases 55
5.2.1.2 Advancements in drug delivery technologies 56
5.2.1.3 Higher patient compliance and preference for oral route 56
5.2.1.4 Expanding therapeutic applications of oral proteins & peptides 57
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of drug development 57
5.2.2.2 Contraindication of oral proteins & peptides 57
5.2.2.3 Stringent regulatory approval process 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides 58
5.2.3.2 Growing demand for personalized medicine 59
5.2.4 CHALLENGES 59
5.2.4.1 Hurdles in formulation and stability 59
5.2.4.2 Availability of alternative therapies 60
5.3 ECOSYSTEM ANALYSIS 61
5.3.1 ROLE OF RAW MATERIAL VENDORS 61
5.3.2 ROLE OF PRODUCT PROVIDERS 62
5.3.3 ROLE OF END USERS 62
5.3.4 ROLE OF REGULATORY AUTHORITIES 62
5.4 VALUE CHAIN ANALYSIS 63
5.5 SUPPLY CHAIN ANALYSIS 65
5.6 PORTER’S FIVE FORCES ANALYSIS 66
5.6.1 THREAT OF NEW ENTRANTS 67
5.6.2 THREAT OF SUBSTITUTES 67
5.6.3 BARGAINING POWER OF SUPPLIERS 68
5.6.4 BARGAINING POWER OF BUYERS 68
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.7 KEY STAKEHOLDERS & BUYING CRITERIA 68
5.7.1 KEY STAKEHOLDERS 68
5.7.2 BUYING CRITERIA 69
5.8 PRICING ANALYSIS 71
5.8.1 PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS 71
5.8.2 PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION 72
5.9 REGULATORY LANDSCAPE 73
5.9.1 REGULATORY SCENARIO 73
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.11 TECHNOLOGY ANALYSIS 77
5.11.1 KEY TECHNOLOGIES 77
5.11.1.1 Transient permeation enhancer 77
5.11.1.2 Gastrointestinal permeation enhancement technology 78
5.11.1.3 Oral sCT (OSTORA) technology 78
5.11.2 COMPLEMENTARY TECHNOLOGIES 78
5.11.2.1 Peptelligence 78
5.11.2.2 ThioMatrix 78
5.11.2.3 Transferrin-based recombinant fusion protein 79
5.11.3 ADJACENT TECHNOLOGIES 79
5.11.3.1 Oramed and Orasome 79
5.11.3.2 Q-sphera 79
5.11.3.3 Nanoinclusion 79
5.11.3.4 Oleotec and Soctec 80
5.12 PIPELINE ANALYSIS 80
5.13 PATENT ANALYSIS 81
5.13.1 METHODOLOGY 81
5.13.2 INNOVATION AND PATENT APPLICATIONS 81
5.13.3 TOP APPLICANTS 81
5.14 KEY CONFERENCES & EVENTS, 2024–2025 83
5.15 INVESTMENT & FUNDING SCENARIO 84
5.16 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET 85
6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE 87
6.1 INTRODUCTION 88
6.2 SEMAGLUTIDE 88
6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH 88
6.3 CALCITONIN 91
6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION 91
6.4 LINACLOTIDE 94
6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH 94
6.5 TROFINETIDE 96
6.5.1 FDA APPROVAL TO SUPPORT GROWTH 96
6.6 VOCLOSPORIN 99
6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION 99
6.7 PLECANATIDE 101
6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH 101
6.8 OTHER MOLECULES 103
7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS 107
7.1 INTRODUCTION 108
7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS 108
7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH 108
7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS 111
7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION 111
 
7.4 GUANYLATE CYCLASE-C AGONISTS 114
7.4.1 RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET 114
7.5 GLYCINE-PROLINE-GLUTAMATE 117
7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH 117
7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS 119
7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH 119
7.7 OTHER DRUG CLASSES 121
8 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA 125
8.1 INTRODUCTION 126
8.2 DIABETES 126
8.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION 126
8.3 CNS DISORDERS 130
8.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 130
8.4 GASTROENTEROLOGY 133
8.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH 133
8.5 GENETIC DISORDERS 136
8.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH 136
8.6 NEPHROLOGY 139
8.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET 139
8.7 OBESITY & OVERWEIGHT 141
8.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH 141
8.8 OTHER THERAPEUTIC AREAS 143
9 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION 146
9.1 INTRODUCTION 147
9.2 TABLETS 147
9.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH 147
9.3 CAPSULES 150
9.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET 150
9.4 ORAL SOLUTIONS 153
9.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH 153
10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER 156
10.1 INTRODUCTION 157
10.2 HOME CARE SETTINGS 157
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH 157
 
10.3 LONG-TERM CARE FACILITIES 160
10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH 160
10.4 HOSPITALS & SPECIALTY CLINICS 163
10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH 163
11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION 167
11.1 INTRODUCTION 168
11.2 NORTH AMERICA 168
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 169
11.2.2 US 173
11.2.2.1 US to hold large share of North American and global markets 173
11.2.3 CANADA 175
11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth 175
11.3 EUROPE 177
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 178
11.3.2 GERMANY 182
11.3.2.1 Germany to hold largest share of European market 182
11.3.3 UK 185
11.3.3.1 Strong focus on advancement of life sciences to support market growth 185
11.3.4 FRANCE 187
11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth 187
11.3.5 ITALY 190
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market 190
11.3.6 SPAIN 192
11.3.6.1 Initiatives associated with GLP-1 drugs to drive market 192
11.3.7 NETHERLANDS 195
11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth 195
11.3.8 REST OF EUROPE 197
11.4 ASIA PACIFIC 199
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 200
11.4.2 CHINA 203
11.4.2.1 Increasing R&D expenditure to drive market 203
11.4.3 JAPAN 206
11.4.3.1 Increasing prevalence of diabetes to drive market 206
11.4.4 INDIA 208
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth 208
11.4.5 AUSTRALIA 211
11.4.5.1 Rising access to GLP-1 drugs and government support to drive market 211
11.4.6 SOUTH KOREA 213
11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth 213
11.4.7 REST OF ASIA PACIFIC 216
11.5 LATIN AMERICA 218
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 218
11.5.2 BRAZIL 221
11.5.2.1 Brazil to hold largest market share in Latin America 221
11.5.3 MEXICO 224
11.5.3.1 Growing diabetes and obesity cases to support market growth 224
11.5.4 REST OF LATIN AMERICA 226
11.6 MIDDLE EAST 229
11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 229
11.6.2 GCC COUNTRIES 232
11.6.2.1 Saudi Arabia 235
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth 235
11.6.2.2 UAE 237
11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to propel market 237
11.6.2.3 Rest of GCC countries 240
11.6.3 REST OF MIDDLE EAST 242
11.7 AFRICA 244
11.7.1 LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET 244
11.7.2 AFRICA: MACROECONOMIC OUTLOOK 244
12 COMPETITIVE LANDSCAPE 248
12.1 OVERVIEW 248
12.2 KEY STRATEGIES/RIGHT TO WIN 248
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES 249
12.3 REVENUE SHARE ANALYSIS 250
12.4 MARKET SHARE ANALYSIS 250
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 252
12.5.1 STARS 252
12.5.2 EMERGING LEADERS 252
12.5.3 PERVASIVE PLAYERS 253
12.5.4 PARTICIPANTS 253
 
12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023 254
12.6.1 STARS 254
12.6.2 EMERGING LEADERS 254
12.6.3 PERVASIVE PLAYERS 254
12.6.4 PARTICIPANTS 254
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 256
12.6.5.1 Company Footprint 256
12.6.5.2 Molecule footprint 258
12.6.5.3 Formulation footprint 258
12.6.5.4 Therapeutic area footprint 259
12.6.5.5 Region footprint 260
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 262
12.7.1 PROGRESSIVE COMPANIES 262
12.7.2 RESPONSIVE COMPANIES 262
12.7.3 DYNAMIC COMPANIES 262
12.7.4 STARTING BLOCKS 262
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 264
12.7.5.1 Detailed list of key startups/SMEs 264
12.7.5.2 Competitive benchmarking of key startups/SMEs 265
12.8 VALUATION & FINANCIAL METRICS 266
12.8.1 FINANCIAL METRICS 266
12.8.2 COMPANY VALUATION 266
12.9 BRAND/PRODUCT COMPARISON 267
12.10 COMPETITIVE SCENARIO 268
12.10.1 PRODUCT APPROVALS 268
12.10.2 DEALS 269
12.10.3 EXPANSIONS 270
12.10.4 OTHER DEVELOPMENTS 270
13 COMPANY PROFILES 272
13.1 INTRODUCTION 272
13.2 KEY PLAYERS 272
13.2.1 NOVO NORDISK A/S 272
13.2.1.1 Business overview 272
13.2.1.2 Products offered 273
13.2.1.3 Recent developments 274
13.2.1.3.1 Product launches & approvals 274
13.2.1.3.2 Expansions 274
13.2.1.3.3 Other developments 275
13.2.1.4 MnM view 275
13.2.1.4.1 Right to win 275
13.2.1.4.2 Strategic choices 275
13.2.1.4.3 Weaknesses & competitive threats 275
13.2.2 ABBVIE INC. 276
13.2.2.1 Business overview 276
13.2.2.2 Products offered 277
13.2.2.3 Recent developments 278
13.2.2.3.1 Product approvals 278
13.2.2.4 MnM view 278
13.2.2.4.1 Right to win 278
13.2.2.4.2 Strategic choices 278
13.2.2.4.3 Weaknesses & competitive threats 279
13.2.3 PFIZER INC. 280
13.2.3.1 Business overview 280
13.2.3.2 Product pipeline 281
13.2.3.3 Recent developments 282
13.2.3.3.1 Product approvals 282
13.2.3.3.2 Deals 282
13.2.3.3.3 Other developments 283
13.2.3.4 MnM view 283
13.2.3.4.1 Right to win 283
13.2.3.4.2 Strategic choices 283
13.2.3.4.3 Weaknesses & competitive threats 283
13.2.4 BAUSCH HEALTH COMPANIES INC. 284
13.2.4.1 Business overview 284
13.2.4.2 Products offered 285
13.2.4.3 Recent developments 286
13.2.4.3.1 Product approvals 286
13.2.5 CHIESI FARMACEUTICI S.P.A. 287
13.2.5.1 Business overview 287
13.2.5.2 Products offered 288
13.2.5.3 Recent developments 288
13.2.5.3.1 Deals 288
13.2.6 ACADIA PHARMACEUTICALS INC. 289
13.2.6.1 Business overview 289
13.2.6.2 Products offered 290
13.2.6.3 Recent developments 290
13.2.6.3.1 Product approvals 290
13.2.7 AURINIA PHARMACEUTICALS INC. 291
13.2.7.1 Business overview 291
13.2.7.2 Products offered 292
13.2.7.3 Recent developments 292
13.2.7.3.1 Product approvals 292
 
13.2.8 MERCK & CO., INC. 293
13.2.8.1 Business overview 293
13.2.8.2 Product pipeline 294
13.2.8.3 Recent developments 295
13.2.8.3.1 Other developments 295
13.2.9 JOHNSON & JOHNSON SERVICES, INC. 296
13.2.9.1 Business overview 296
13.2.9.2 Product pipeline 297
13.2.9.3 Recent developments 298
13.2.9.3.1 Other developments 298
13.2.10 SWK HOLDINGS 299
13.2.10.1 Business overview 299
13.2.10.2 Product pipeline 300
13.2.10.3 Recent developments 300
13.2.10.3.1 Other developments 300
13.2.11 R-PHARM JSC 301
13.2.11.1 Business overview 301
13.2.11.2 Products in pipeline 301
13.2.12 ENTERA BIO LTD. 302
13.2.12.1 Business overview 302
13.2.12.2 Product pipeline 302
13.2.12.3 Recent developments 303
13.2.12.3.1 Deals 303
13.2.12.3.2 Other developments 303
13.2.13 PROXIMA CONCEPTS 304
13.2.13.1 Business overview 304
13.2.13.2 Products in pipeline 304
13.3 OTHER PLAYERS 305
13.3.1 ASTRAZENECA PLC 305
13.3.2 REGOR THERAPEUTICS GROUP 305
13.3.3 TERNS PHARMACEUTICALS, INC. 306
13.3.4 STRUCTURE THERAPEUTICS 306
13.3.5 VIKING THERAPEUTICS 307
13.3.6 PROTAGONIST THERAPEUTICS INC. 307
13.3.7 RANI THERAPEUTICS 308
13.3.8 CARMOT THERAPEUTICS, INC. 308
13.3.9 ZEALAND PHARMA 309
13.3.10 SCIWIND BIOSCIENCES CO., LTD. 309
13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 310
 
14 APPENDIX 311
14.1 DISCUSSION GUIDE 311
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 315
14.3 CUSTOMIZATION OPTIONS 317
14.4 RELATED REPORTS 317
14.5 AUTHOR DETAILS 318